反应详情

Following a procedure analogous to that for the synthesis of Intermediate 1A, N,N-dibutyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazole-3-carboxamide (355 mg, 1.01 mmol) was converted to the title compound (327 mg, 79%). 1H NMR (CD3OD) δ 4.60 (t, J=3.4 Hz, 1H), 3.94 (td, J=9.7, 6.5 Hz, 1H), 3.79-3.61 (m, 2 H), 3.59-3.41 (m, 3H), 3.39-3.25 (m, 2H), 3.04-2.91 (m, 2H), 1.87-1.34 (m, 12H), 1.27-1.09 (m, 2H), 0.99 (t, J=7.3 Hz, 3H), 0.81 (t, J=7.4 Hz, 3H); MS(ESI+) m/z 386.3 (M+H)+.